Abstract:Immunotherapy offers the potential for durable clinical benefit but calls into question the association between tumor size and outcome that currently forms the basis for imaging-guided treatment. Artificial intelligence (AI) and radiomics allow for discovery of novel patterns in medical images that can increase radiology’s role in management of patients with cancer, although methodological issues in the literature limit its clinical application. Using keywords related to immunotherapy and radiomics, we performed a literature review of MEDLINE, CENTRAL, and Embase from database inception through February 2022. We removed all duplicates, non-English language reports, abstracts, reviews, editorials, perspectives, case reports, book chapters, and non-relevant studies. From the remaining articles, the following information was extracted: publication information, sample size, primary tumor site, imaging modality, primary and secondary study objectives, data collection strategy (retrospective vs prospective, single center vs multicenter), radiomic signature validation strategy, signature performance, and metrics for calculation of a Radiomics Quality Score (RQS). We identified 351 studies, of which 87 were unique reports relevant to our research question. The median (IQR) of cohort sizes was 101 (57–180). Primary stated goals for radiomics model development were prognostication (n=29, 33.3%), treatment response prediction (n=24, 27.6%), and characterization of tumor phenotype (n=14, 16.1%) or immune environment (n=13, 14.9%). Most studies were retrospective (n=75, 86.2%) and recruited patients from a single center (n=57, 65.5%). For studies with available information on model testing, most (n=54, 65.9%) used a validation set or better. Performance metrics were generally highest for radiomics signatures predicting treatment response or tumor phenotype, as opposed to immune environment and overall prognosis. Out of a possible maximum of 36 points, the median (IQR) of RQS was 12 (10–16). While a rapidly increasing number of promising results offer proof of concept that AI and radiomics could drive precision medicine approaches for a wide range of indications, standardizing the data collection as well as optimizing the methodological quality and rigor are necessary before these results can be translated into clinical practice.

Historical perspective and future directions: computational science in immuno-oncology

Computational immunogenomic approaches to predict response to cancer immunotherapies

Ten challenges and opportunities in computational immuno-oncology

Facts and hopes in using omics to advance combined immunotherapy strategies

Technological Advances in Cancer Immunity: from Immunogenomics to Single-Cell Analysis and Artificial Intelligence

The Past, Present and Future of Immunotherapy Against Tumor.

Immunotherapy and next-generation sequencing guided therapy for precision oncology: what have we learnt and what does the future hold?

The Multi-Omics Perspective

Computational methods and biomarker discovery strategies for spatial proteomics: a review in immuno-oncology

Navigating the Immune Maze: Pioneering Strategies for Un-shackling Cancer Immunotherapy Resistance

Spatial omics techniques and data analysis for cancer immunotherapy applications

Future perspectives in cancer immunotherapy.

Bioinformatics for cancer immunotherapy target discovery

The Immunoscore: Colon Cancer and Beyond

Artificial intelligence and radiomics: fundamentals, applications, and challenges in immunotherapy

Single-Cell Informatics for Tumor Microenvironment and Immunotherapy

Artificial Intelligence-based Radiomics in the Era of Immuno-Oncology

Tumor immunology CRISPR screening: present, past, and future

Immuno-oncology Combinations: A Review of Clinical Experience and Future Prospects

The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy

Quantitative multiplexed imaging technologies for single-cell analysis to assess predictive markers for immunotherapy in thoracic immuno-oncology: promises and challenges